Anti-apolipoprotein A-1 autoantibodies as risk biomarker for cardiovascular diseases in type 2 diabetes mellitus

Autor: Mona Kafoury, Eman Awadallah, Enas Abdel Rasheed, Ingy Ashmawy, Dalia El-Lebedy, Dalia Abd-El Haleem
Rok vydání: 2015
Předmět:
0301 basic medicine
Male
endocrine system diseases
Diabetic Cardiomyopathies
Endocrinology
Diabetes and Metabolism
Type 2 diabetes
030204 cardiovascular system & hematology
Gastroenterology
chemistry.chemical_compound
0302 clinical medicine
Endocrinology
Risk Factors
Prevalence
Incidence (epidemiology)
Incidence
Middle Aged
Cholesterol
Cardiovascular Diseases
Biomarker (medicine)
lipids (amino acids
peptides
and proteins)
Egypt
Female
Adult
medicine.medical_specialty
Hypercholesterolemia
Diabetic angiopathy
Sensitivity and Specificity
Autoimmune Diseases
03 medical and health sciences
Internal medicine
Diabetes mellitus
Internal Medicine
medicine
Humans
Autoantibodies
Apolipoprotein A-I
business.industry
Autoantibody
nutritional and metabolic diseases
Type 2 Diabetes Mellitus
Cholesterol
LDL
medicine.disease
030104 developmental biology
chemistry
Diabetes Mellitus
Type 2
Immunology
Asymptomatic Diseases
business
Biomarkers
Diabetic Angiopathies
Zdroj: Journal of diabetes and its complications. 30(4)
ISSN: 1873-460X
Popis: Anti-Apolipoprotein A-1 autoantibodies (anti-ApoA-1 IgG) represent an emerging prognostic cardiovascular marker in patients with myocardial infarction or autoimmune diseases associated with high thrombotic events. The aim of this work is to investigate the incidence of anti-apoA-1 autoantibodies in type 2 diabetes (T2DM) patients with and without CVD and to study potential association with disease risk and its effect on plasma lipid parameters.Qualitative determination of anti-apoA-1 IgG was assayed in sera from 302 subjects classified into T2DM patients (n=102), T2DM+CVD (n=112) and healthy controls (n=88).The incidence of anti-apoA-1 IgG was significantly higher among CVD patients (35.7%) than T2DM patients (8.8%) or control subjects (6.1%), p0.0001. A significant association with CVD was identified (p0.0001) and subjects who were positive for anti-apoA-1 IgG were at 8.5 times increased risk to develop CVD when compared to controls. Diabetic patients who were positive for the antibodies showed 5.7 times increased CVD risk. ROC analysis indicated anti-apoA-1 IgG as a risk biomarker for CVD in T2DM patients with an AUC value of 0.76, sensitivity of 35.7% and specificity of 91.2%. Studying the effect on lipid parameters, anti-apoA-1 IgG associated with significantly higher serum concentrations of TC and non-HDL-C in all groups and with higher concentrations of LDL-C in diabetic patients and higher TC/HDL-C ratio in CVD patients.Our results indicate that anti-apoA-1 IgG is a cardiovascular risk biomarker in T2DM patients.
Databáze: OpenAIRE
Externí odkaz: